Evidence map›Paper›PMID 32714998›Full record

ArticleAsia Oceania journal of nuclear medicine & biology2020

Preclinical study of a new

Hossein Behnammanesh, Mostafa Erfani, Maliheh Hajiramezanali, Safura Jokar, Parham Geramifar, Omid Sabzevari, Mohsen Amini, Seyed Mohammad Mazidi, Davood Beiki

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asia Oceania journal of nuclear medicine & biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Chemo-radiotherapy withFrontiers in medicine · 2023
    Article
  2. Review
  3. Application of phototherapeutic-based nanoparticles in colorectal cancer.International journal of biological sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hossein BehnammaneshDepartment of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mostafa ErfaniRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
Maliheh HajiramezanaliDepartment of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Safura JokarDepartment of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Parham GeramifarResearch Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Omid SabzevariDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
Mohsen AminiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Mohammad MazidiRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
Davood BeikiResearch Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRAtomic Energy Organization of Iran · IRNuclear Science and Technology Research Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSomatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years. The better biomedical properties of radioantagonists as higher tumor uptake make these radioligands more attractive than agonists for somatostatin receptor-targeted radionuclide therapy. In this study, we tried to evaluate the efficiency of Luthetium-177 (

methodsDOTA conjugated antagonistic peptide with the sequence of p-Cl-Phe-Cyclo(D-Cys-L-BzThi-D-Aph-Lys-Thr-Cys)-D-Tyr-NH2 (DOTA-Peptide 2) was labeled with

results

conclusion

Indexed as

Antagonistic peptideHuman colon- adenocarcinoma cellsLutetium-177Somatostatin

Identifiers

PMID32714998
PMCPMC7354249
OpenAlexW3040907792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.